Czechia· CZ-0289973

BOSUTINIB MSN

A bosutinib product containing bosutinib dihydrate, registered in Czechia by MSN LABS EUROPE Limited, Paola. The same ATC class is registered in 15 of our 19 countries.

ATC L01EA04

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedBOSUTINIB MSNATCL01EA04REGISTER NO.CZ-0289973PACKS LISTED0CHECKEDSeptember 28, 2026

Where it is registered

Bosutinib is registered in 15 of 19 countries.

Countries holding a registration under ATC L01EA04 (bosutinib), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 8 of them publish a price we can compare per daily dose

Bosutinib · ATC L01EA04

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of bosutinib costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Bosutinib · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

  • CH Switzerland$65.58
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

SÚKL (Czech Republic)
Active substance
BOSUTINIB DIHYDRATE
Manufacturer
MSN LABS EUROPE Limited, Paola
Country
Czechia (CZ)
ATC code
L01EA04
ATC class
Bosutinib
Defined daily dose
0.4 g, O
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

469 interactions on record for bosutinib.

Graded by severity as the source publishes them — 159 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Bosutinib · interactions on record

469 records

  • 159 severe
  • 307 moderate
  • 3 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • AprepitantA04AD12severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Bosutinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bosutinib products

Authorised across Europe · EMA

The same active substance is authorised in 27 EEA countries. Names it is sold under:

  • Austria · Bosutinib Sandoz, Bosutinib Teva
  • Belgium · Bosutinib Eg, Bosutinib Eg (Eurogeneric)
  • Bulgaria · Босутиниб Msn, Босутиниб Зентива
  • Germany · Bosutinib, Bosutinib Al
  • Denmark · Bosutinib Newbury, Bosutinib Sandoz
  • Estonia · Bosutinib Msn
  • Spain · Bosutinib, Bosutinib Vivanta
  • Finland · Bosutinib Stada
  • France · Bosutinib Biogaran, Bosutinib Eg Labo
  • United Kingdom (Northern Ireland) · Bosutinib Dr. Reddy’s, Bosutinib Stada
  • Croatia · Bosutinib Msn, Bosutinib Onkogen
  • Hungary · Bosutinib Onkogen, Bosutinib Sandoz
  • Ireland · Bosutinib Clonmel, Bosutinib Rowex
  • Iceland · Bosulif, Bosutinib Beta
  • Italy · Bosutinib Dr. Reddys, Bosutinib Eg
  • Liechtenstein · Bosulif
  • Lithuania · Bosutinib Msn
  • Luxembourg · Bosutinib Eg
  • Latvia · Bosutinib Msn
  • Malta · Bosutinib, Bosutinib Lotus
  • Netherlands · Bosutinib, Bosutinib Cf
  • Norway · Bosulif, Bosutinib Newbury
  • Poland · Bosutinib Msn, Bosutinib Onkogen
  • Portugal · Bosutinib Teva
  • Romania · Bosutinib Teva
  • Sweden · Bosutinib Newbury, Bosutinib Sandoz
  • Slovenia · Bosutinib Msn

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/01c834e7-5300-41f3-82ca-78a57a6b5b53
GET /v1/drugs/01c834e7-5300-41f3-82ca-78a57a6b5b53?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "TBL FLM",
  "source": "sukl",
  "strength": "500MG",
  "pack_size": "30X1",
  "substance": "BOSUTINIB DIHYDRATE",
  "cz_kod_sukl": "0289973",
  "product_type": "CH",
  "substance_codes": "2666",
  "registration_state": "R",
  "registration_number": "44/223/23-C"
}

See everything about bosutinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.